Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors
| Autor: | Shoko Matsui, Kotaro Tokui, Kazuyuki Tobe, Toshiro Miwa, Chihiro Taka, Naoki Takata, Kenji Azechi, Shingo Imanishi, Seisuke Okazawa, Kana Hayashi, Satoshi Nomura, Ryuji Hayashi, Isami Mizushima, Minehiko Inomata, Kenta Kambara |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Cancer Research Lung Neoplasms Immune checkpoint inhibitors Pembrolizumab Pleomorphic carcinoma General Biochemistry Genetics and Molecular Biology Carboplatin chemistry.chemical_compound Humans Medicine Sarcomatoid carcinoma Immune Checkpoint Inhibitors Lung Aged Pharmacology Tumor size business.industry Carcinoma Middle Aged medicine.disease Regimen medicine.anatomical_structure chemistry Cancer research business Research Article |
| Zdroj: | In Vivo |
| ISSN: | 1791-7549 0258-851X |
| DOI: | 10.21873/invivo.12428 |
| Popis: | Aim We report, herein, three cases of pleomorphic carcinoma of the lung treated with immune checkpoint inhibitors. Case 1: A 73-year-old man was diagnosed as having pleomorphic carcinoma of the lung and treated with pembrolizumab alone. However, he showed no response and died 4 months after the initiation of the treatment. Case 2: A 66-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on a combination regimen of pembrolizumab plus carboplatin plus nab-paclitaxel, and a remarkable response was observed. Case 3: A 49-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on pembrolizumab monotherapy as second-line treatment. Eleven months after the treatment initiation, computed tomography revealed the decrease of tumor diameter. Conclusion Immune checkpoint inhibitor therapy is expected to improve the prognosis of patients with pleomorphic carcinoma of the lung. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|